These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 31563836

  • 1. Lipoprotein apheresis efficacy, challenges and outcomes: A descriptive analysis from the UK Lipoprotein Apheresis Registry, 1989-2017.
    Pottle A, Thompson G, Barbir M, Bayly G, Cegla J, Cramb R, Dawson T, Eatough R, Kale V, Neuwirth C, Nicholson K, Payne J, Scott J, Soran H, Walji S, Watkins S, Weedon H, Nath Datta DB.
    Atherosclerosis; 2019 Nov; 290():44-51. PubMed ID: 31563836
    [Abstract] [Full Text] [Related]

  • 2. A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry).
    Kayikcioglu M, Tokgozoglu L, Yilmaz M, Kaynar L, Aktan M, Durmuş RB, Gokce C, Temizhan A, Ozcebe OI, Akyol TK, Okutan H, Sag S, Gul OO, Salcioglu Z, Yenercag M, Altunkeser BB, Kuku I, Yasar HY, Kurtoglu E, Kose MD, Demircioglu S, Pekkolay Z, Ilhan O.
    Atherosclerosis; 2018 Mar; 270():42-48. PubMed ID: 29407887
    [Abstract] [Full Text] [Related]

  • 3. High serum triglyceride concentrations in patients with homozygous familial hypercholesterolemia attenuate the efficacy of lipoprotein apheresis by dextran sulfate adsorption.
    Drouin-Chartier JP, Tremblay AJ, Bergeron J, Lamarche B, Couture P.
    Atherosclerosis; 2018 Mar; 270():26-32. PubMed ID: 29407885
    [Abstract] [Full Text] [Related]

  • 4. Cardiovascular outcomes in patients with homozygous familial hypercholesterolaemia on lipoprotein apheresis initiated during childhood: long-term follow-up of an international cohort from two registries.
    Reijman MD, Tromp TR, Hutten BA, Hovingh GK, Blom DJ, Catapano AL, Cuchel M, Dann EJ, Gallo A, Hudgins LC, Raal FJ, Ray KK, Sadiq F, Soran H, Groothoff JW, Wiegman A, Kusters DM, Homozygous Familial Hypercholesterolaemia International Clinical Collaborators (HICC), Children with Homozygous Hypercholesterolemia on Lipoprotein Apheresis: an International Registry (CHAIN) consortia.
    Lancet Child Adolesc Health; 2024 Jul; 8(7):491-499. PubMed ID: 38759658
    [Abstract] [Full Text] [Related]

  • 5. Long-term lipoprotein apheresis in the treatment of severe familial hypercholesterolemia refractory to high intensity statin therapy: Three year experience at a lipoprotein apheresis centre.
    Mickiewicz A, Borowiec-Wolna J, Bachorski W, Gilis-Malinowska N, Gałąska R, Raczak G, Chmara M, Wasąg B, Jaguszewski MJ, Fijałkowski M, Gruchała M.
    Cardiol J; 2019 Jul; 26(6):669-679. PubMed ID: 30234904
    [Abstract] [Full Text] [Related]

  • 6. Current insights into the German Lipoprotein Apheresis Registry (GLAR) - Almost 5 years on.
    Schettler VJJ, Neumann CL, Peter C, Zimmermann T, Julius U, Roeseler E, Heigl F, Grützmacher P, Blume H, Scientific Board of GLAR for the German Apheresis Working Group.
    Atheroscler Suppl; 2017 Nov; 30():50-55. PubMed ID: 29096861
    [Abstract] [Full Text] [Related]

  • 7. Practice of lipoprotein apheresis and short-term efficacy in children with homozygous familial hypercholesterolemia: Data from an international registry.
    Luirink IK, Hutten BA, Greber-Platzer S, Kolovou GD, Dann EJ, de Ferranti SD, Taylan C, Bruckert E, Saheb S, Oh J, Driemeyer J, Farnier M, Pape L, Schmitt CP, Novoa FJ, Maeser M, Masana L, Shahrani A, Wiegman A, Groothoff JW.
    Atherosclerosis; 2020 Apr; 299():24-31. PubMed ID: 32199148
    [Abstract] [Full Text] [Related]

  • 8. The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years on.
    Schettler VJJ, Neumann CL, Peter C, Zimmermann T, Julius U, Roeseler E, Heigl F, Grützmacher P, Blume H, Vogt A, Scientific Board of GLAR for the German Apheresis Working Group.
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):44-49. PubMed ID: 28233268
    [Abstract] [Full Text] [Related]

  • 9. What have we learned from Turkish familial hypercholesterolemia registries (A-HIT1 and A-HIT2)?
    Kayikcioglu M, Tokgozoglu L, Dogan V, Ceyhan C, Tuncez A, Kutlu M, Onrat E, Alici G, Akbulut M, Celik A, Yesilbursa D, Sahin T, Sonmez A, Ozdogan O, Temizhan A, Kilic S, Bayram F, Sabuncu T, Coskun FY, Ildizli M, Durakoglugil E, Kirilmaz B, Yilmaz MB, Yigit Z, Yildirim AB, Gedikli O, Topcu S, Oğuz A, Demir M, Yenerçağ M, Yıldırır A, Demircan S, Yilmaz M, Kaynar LG, Aktan M, Durmus RB, Gokce C, Ozcebe Oİ, Akyol TK, Okutan H, Sag S, Gul OO, Salcioglu Z, Altunkeser BB, Kuku I, Yasar HY, Kurtoglu E, Kose MD, Demircioglu S, Pekkolay Z, Ilhan O, Can LH.
    Atherosclerosis; 2018 Oct; 277():341-346. PubMed ID: 30270069
    [Abstract] [Full Text] [Related]

  • 10. Cardiovascular events in patients with familial hypercholesterolemia and hyperlipoproteinaemia (a): Indications for lipoprotein apheresis in Poland.
    Mickiewicz A, Marlega J, Kuchta A, Bachorski W, Cwiklinska A, Raczak G, Gruchala M, Fijalkowski M.
    J Clin Apher; 2021 Jun; 36(3):370-378. PubMed ID: 33386762
    [Abstract] [Full Text] [Related]

  • 11. The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.
    Stefanutti C, Blom DJ, Averna MR, Meagher EA, Theron Hd, Marais AD, Hegele RA, Sirtori CR, Shah PK, Gaudet D, Vigna GB, Sachais BS, Di Giacomo S, du Plessis AM, Bloedon LT, Balser J, Rader DJ, Cuchel M, Phase 3 HoFH Lomitapide Study Investigators.
    Atherosclerosis; 2015 Jun; 240(2):408-14. PubMed ID: 25897792
    [Abstract] [Full Text] [Related]

  • 12. Long-term outcome in 53 patients with homozygous familial hypercholesterolaemia in a single centre in France.
    Bruckert E, Kalmykova O, Bittar R, Carreau V, Béliard S, Saheb S, Rosenbaum D, Bonnefont-Rousselot D, Thomas D, Emery C, Khoshnood B, Carrié A.
    Atherosclerosis; 2017 Feb; 257():130-137. PubMed ID: 28131047
    [Abstract] [Full Text] [Related]

  • 13. HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom.
    France M, Rees A, Datta D, Thompson G, Capps N, Ferns G, Ramaswami U, Seed M, Neely D, Cramb R, Shoulders C, Barbir M, Pottle A, Eatough R, Martin S, Bayly G, Simpson B, Halcox J, Edwards R, Main L, Payne J, Soran H, for HEART UK Medical Scientific and Research CommitteeDepartment of Medicine and Cardiovascular Trials Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, M139WL, UK; Cardiovascular Research Group, University of Manchester, Manchester, M139WL, UK..
    Atherosclerosis; 2016 Dec; 255():128-139. PubMed ID: 27839699
    [Abstract] [Full Text] [Related]

  • 14. Analysis of circulating miRNAs in patients with familial hypercholesterolaemia treated by LDL/Lp(a) apheresis.
    Dlouha D, Blaha M, Blaha V, Fatorova I, Hubacek JA, Stavek P, Lanska V, Parikova A, Pitha J.
    Atheroscler Suppl; 2017 Nov; 30():128-134. PubMed ID: 29096828
    [Abstract] [Full Text] [Related]

  • 15. Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?
    Schettler VJJ, Ringel J, Jacob S, Julius U, Klingel R, Heigl F, Roeseler E, Grützmacher P, German Society of Nephrology (DGfN) and the Foundation of German Centers of Nephrology (DN).
    Atheroscler Suppl; 2017 Nov; 30():44-49. PubMed ID: 29096860
    [Abstract] [Full Text] [Related]

  • 16. Treatment of homozygous familial hypercholesterolaemia in paediatric patients: A monocentric experience.
    Buonuomo PS, Macchiaiolo M, Leone G, Valente P, Mastrogiorgio G, Gnazzo M, Rana I, Gonfiantini MV, Gagliardi MG, Romano F, Bartuli A.
    Eur J Prev Cardiol; 2018 Jul; 25(10):1098-1105. PubMed ID: 29785886
    [Abstract] [Full Text] [Related]

  • 17. Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany.
    Heigl F, Hettich R, Lotz N, Reeg H, Pflederer T, Osterkorn D, Osterkorn K, Klingel R.
    Atheroscler Suppl; 2015 May; 18():154-62. PubMed ID: 25936320
    [Abstract] [Full Text] [Related]

  • 18. Multimodal lipid-lowering treatment in pediatric patients with homozygous familial hypercholesterolemia-target attainment requires further increase of intensity.
    Klaus G, Taylan C, Büscher R, Schmitt CP, Pape L, Oh J, Driemeyer J, Galiano M, König J, Schürfeld C, Spitthöver R, Schaefer JR, Weber LT, Heibges A, Klingel R.
    Pediatr Nephrol; 2018 Jul; 33(7):1199-1208. PubMed ID: 29502162
    [Abstract] [Full Text] [Related]

  • 19. Contemporary lipid-lowering management and risk of cardiovascular events in homozygous familial hypercholesterolaemia: insights from the Italian LIPIGEN Registry.
    D'Erasmo L, Bini S, Casula M, Gazzotti M, Bertolini S, Calandra S, Tarugi P, Averna M, Iannuzzo G, Fortunato G, Catapano AL, Arca M, LIPIGEN HoFH group .
    Eur J Prev Cardiol; 2024 Jun 03; 31(8):1038-1047. PubMed ID: 38374534
    [Abstract] [Full Text] [Related]

  • 20. Actual situation of lipoprotein apheresis in Saxony in 2013.
    Emmrich U, Hohenstein B, Julius U.
    Atheroscler Suppl; 2015 May 03; 18():215-25. PubMed ID: 25936329
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.